Glucagon-like peptide-1 receptor agonists and risk for cardiovascular events in older adults treated with levothyroxine: a target trial emulation
In patients with T2D historically treated with stable doses of levothyroxine, GLP-1RA initiation was associated with a higher risk of AF/Aflutter. Further research is warranted to investigate the potential roles of weight loss, TSH fluctuations, and levothyroxine dose adjustment after GLP-1RA in mediating the cardiovascular risk.
Authors
- TIANZE JIAO
- Rozalina Grubina McCoy (ORCID: https://orcid.org/0000-0002-2289-3183)
- Brian Cicali (ORCID: https://orcid.org/0000-0002-7932-8599)
- Fanxing Du
- Juan Pablo Brito (ORCID: https://orcid.org/0000-0003-1840-1745)
- Naykky Singh Ospina (ORCID: https://orcid.org/0000-0003-4240-6239)
- Stephan Schmidt
- Hui Shao
- Yishan Chen (ORCID: https://orcid.org/0009-0001-5474-5900)
- Qing Liu
Institutions
- University of Maryland, Baltimore (US)
- Mayo Clinic (US)
- Emory University (US)
- American Association of Colleges of Pharmacy (US)
- Foundation for the National Institutes of Health (US)
- WinnMed (US)
- University of Florida (US)
- Woodruff Health Sciences Center (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Cardiovascular Diabetology
- Published
- 2025-12-24
- DOI
- https://doi.org/10.1186/s12933-025-02971-7
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29